MLTX - MoonLake Immunotherapeutics AG Profit before interest, taxes and amortization
MoonLake Immunotherapeutics (MLTX) is implementing AI to accelerate the development of biologics, focusing on the treatment of severe autoimmune pathologies of the skin and joints. An EBITDA cash flow chart is available in the GURU.Markets system, where the current figure is 0.00. This metric helps assess real operating profit as the company mitigates the risks of a single-product model by expanding the application of sonelokimab in rheumatology.
Summary analytical data breakdowns for MoonLake (MLTX)
- current quotes and average value forecast:
- market capitalization statistics:
- book capitalization data:
- company total debt and liquidity indicators:
Debt to Equity MoonLake Immunotherapeutics|MLTX - Long-Term Debt to Equity|Current Liabilities to Capital MoonLake Immunotherapeutics AG|MLTX - Company Debts|Debt to Book Capitalization Ratio MoonLake Immunotherapeutics|MLTX - Company Long-Term Debts|Short-Term Debt Volume MoonLake Immunotherapeutics|Interim Coverage Ratio moonlaketx.com
- financial results and valuation multiples details:
MLTX - Company Net Income|Future Profit MoonLake Immunotherapeutics|MLTX - Price to Earnings Ratio|Projected Price to Earnings moonlaketx.com|MLTX - Price/Earnings to Growth Ratio|Company Value to EBITDA MoonLake Immunotherapeutics|MLTX - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months MoonLake Immunotherapeutics|MLTX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months moonlaketx.com|MLTX - Earnings per share growth in current year|Net earnings per share growth forecast for next year MoonLake Immunotherapeutics
- sales revenue and business income indicators:
Analysis of all company metrics:MoonLake Corp (MLTX)
Professional managers filter assets using cash flow stripped of GAAP paper adjustments to identify real operational efficiency. This metric measures the actual cash balance from core activities, which is critical for MoonLake Immunotherapeutics (MLTX), whose nanotechnology developments require colossal capital expenditures for FDA clinical trials; therefore, any growth in EBITDA reduces the risk of overpayment.
Who MoonLake Immunotherapeutics competes with
ASND - Operating profit before deduction of amortization|Madrigal Pharmaceuticals - Operating profit EBITDA|Profit before interest, taxes and amortization corcept.com|RYTM (Rhythm Pharmaceuticals, Inc.) - Operating profit before deduction of amortization|AKRO: Company profit before taxes, interest and amortization|MTSR (Metsera Corp) - Operating profit EBITDA|Operating profit EBITDA Crinetics Corp|Operating profit EBITDA NAMS|Profit before payment of interest, taxes and amortization SLNO (soleno.life)|Profit before payment of interest, taxes and amortization Amicus Therapeutics, Inc. FOLD|89bio Inc (ETNB) - Profit before interest, taxes and amortization|AGIO - Profit before payment of interest, taxes and amortization|GPCR: Profit before payment of interest, taxes and amortization|MDXG: Operating profit EBITDA|RZLT - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Lexicon Pharmaceuticals, Inc.|MBX Biosciences, Inc. (MBX) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Altimmune Corp (ALT)|Operating profit before deduction of amortization Aardvark Pharma AARD|Profit before payment of interest, taxes and amortization Sagimet Biosciences SGMT|BIOA - Operating profit before deduction of amortization|BMEA - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Quince Therapeutics|Fractyl (GUTS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization vTv Therapeutics (VTVT)|Profit before payment of interest, taxes and amortization Agape ATP Corp|Operating profit before amortization PLUR (Pluri Inc)|Profit before payment of interest, taxes and amortization Synlogic, Inc. (SYBX)|Profit before payment of interest, taxes and amortization LPCN (Lipocine Inc)|Operating profit EBITDA MTNB (Matinas BioPharma Holdings)|Operating profit EBITDA sprucebiosciences.com SPRB|GLTO - Profit before payment of interest, taxes and amortization|CTCX - Operating profit EBITDA|LUMO: Operating profit EBITDA|Profit before interest, taxes and amortization Organovo Holdings (ONVO)|Operating profit before deduction of amortization RDUS
